Coronary Heart Disease Diagnostic Imaging Devices Market by Technology (CT, MRI, Optical Imaging), Application (Anatomical Assessment, Perfusion Imaging, Viability Imaging), End User - Global Forecast 2025-2032
Description
The Coronary Heart Disease Diagnostic Imaging Devices Market was valued at USD 2.58 billion in 2024 and is projected to grow to USD 2.84 billion in 2025, with a CAGR of 10.71%, reaching USD 5.82 billion by 2032.
A focused orientation on how diagnostic imaging innovations and clinical imperatives are reshaping coronary heart disease detection, management, and care pathways
This executive summary provides a concise but comprehensive orientation to the evolving diagnostic imaging landscape for coronary heart disease, synthesizing technological advances, clinical practice shifts, and policy drivers that are shaping care pathways today. The intent is to equip healthcare leaders, device manufacturers, and clinical innovators with a clear view of the forces that define diagnostic choices, patient flow, and investment priorities across acute and outpatient settings.
To accomplish this, the narrative integrates clinical imperatives with device-level capabilities, emphasizes interoperability and workflow integration, and highlights how imaging modalities enable earlier detection, risk stratification, and therapy planning. By focusing on diagnostic value rather than output metrics, the summary outlines how imaging contributes to clinical decision-making, from anatomical characterization through perfusion and viability assessment, and positions imaging as an integral component of a patient-centric cardiovascular strategy.
How rapid hardware advancements, software-driven analytics, and care delivery model shifts are collectively redefining diagnostic imaging strategies for coronary heart disease
The diagnostic ecosystem for coronary heart disease is undergoing transformative shifts driven by faster volumetric acquisition, improved tissue characterization, and software-enabled interpretation. Advances in computed tomography now permit higher temporal and spatial resolution that supports low-dose coronary angiography and functional assessment in a single session. Concurrently, magnetic resonance imaging has extended its role beyond morphology to include refined quantitative perfusion and scar characterization, offering clinicians multiparametric insights without ionizing radiation.
Software convergence is accelerating change through artificial intelligence and advanced post-processing that automate segmentation, quantify perfusion, and generate reproducible biomarkers. These capabilities support triage in emergency departments, outpatient pre-procedural planning, and longitudinal disease monitoring. In parallel, workflow and care delivery models are evolving: imaging is migrating from tertiary centers into ambulatory and diagnostic center settings, while hybrid protocols that combine anatomical and physiological evaluation are increasingly adopted to reduce diagnostic uncertainty and guide intervention. Taken together, these shifts favor integrated solutions that pair modality-specific hardware improvements with cloud-native analytics and robust clinical validation.
Understanding the multi-dimensional ramifications of the 2025 tariff landscape on supply chains, procurement strategies, and device access across diagnostic imaging networks
The introduction of additional tariffs and trade adjustments in 2025 has created measurable pressure across the diagnostic imaging supply chain, prompting device vendors and healthcare providers to reassess procurement strategies and production footprints. Tariff-related input cost increases have particularly affected capital-intensive components and subassemblies, leading manufacturers to explore regional sourcing, revised supplier agreements, and strategic inventory positioning to mitigate lead-time exposures.
As a consequence, healthcare providers are confronting higher acquisition and service costs for certain imported imaging systems and parts, which has accelerated interest in refurbished systems, extended service contracts, and bundled financing. Policy responses and commercial strategies have emerged to preserve access: vendors are reconfiguring distribution models to localize key components, contract manufacturers are being engaged to diversify assembly locations, and providers are emphasizing total cost of ownership in procurement dialogues. Collectively, these adaptations aim to maintain clinical continuity while absorbing incremental cost pressures, and they underscore the importance of transparent supply chain mapping and proactive engagement with procurement and clinical stakeholders.
Deep segmentation insights that link modality classes, clinical applications, and care settings to optimize technology selection and workflow alignment for coronary diagnostics
A segmentation-centric view reveals where clinical need, technology capability, and care setting converge to influence adoption patterns. Across technology archetypes, computed tomography remains central for rapid coronary anatomical assessment, supported by distinct CT system classes such as dual-source CT that enable high temporal resolution, multi-slice CT platforms that balance coverage and throughput, and single-slice configurations that continue to serve lower-volume or niche use cases. Magnetic resonance imaging contributes complementary soft-tissue contrast and functional evaluation, delivered across field strengths that include 1.5T systems for broad clinical access, 3T platforms for higher signal-to-noise applications, and above 3T options in specialized research and advanced clinical centers.
Optical imaging modalities like intravascular optical coherence tomography and near-infrared spectroscopy advance vessel-level characterization during interventional workflows, while nuclear techniques including PET and SPECT provide molecular and metabolic insights that enhance viability and inflammation assessment. Ultrasound remains indispensable for bedside evaluation, evolving across 2D platforms for rapid anatomical assessment, 3D systems that enhance volumetric visualization, and Doppler modalities that quantify hemodynamic flow. End-user dynamics matter: ambulatory care centers and diagnostic centers are increasingly optimized for high-throughput non-invasive imaging, hospitals remain the focal point for acute, hybrid, and interventional diagnostics, and specialty clinics concentrate on longitudinal management. Application-driven segmentation further clarifies utility, spanning anatomical assessment for structural delineation, perfusion imaging for physiological evaluation with both resting and stress protocols, and viability imaging to inform revascularization and device therapy decisions. When considered together, these segmentation lenses underscore that procurement and deployment decisions should align modality selection with clinical pathways, throughput expectations, and the downstream implications for interventional planning and longitudinal patient management.
How regional policy frameworks, care delivery infrastructures, and capital investment patterns are driving differentiated adoption curves for coronary diagnostic imaging across global markets
Regional dynamics shape technology adoption, reimbursement pathways, and infrastructure investment in distinct ways across the globe. In the Americas, clinical guidelines, private payer frameworks, and a robust network of tertiary and community hospitals support rapid uptake of advanced CT and MRI protocols, while ambulatory diagnostic centers increasingly handle outpatient imaging volumes. Investment in integrated informatics and remote image review capabilities is notable, enabling broad clinician access despite geographic dispersion.
Europe, the Middle East and Africa exhibit heterogeneity driven by national health system priorities, regulatory landscapes, and variable capital availability. In several European markets, reimbursement alignment and centralized care pathways favor high-value imaging protocols and cross-center collaboration. The Middle East has accelerated capital investment in flagship centers, often targeting advanced modality installations and interventional imaging. Africa presents a mix of challenges and opportunity, with infrastructure constraints prompting interest in portable and cost-efficient ultrasound and cloud-enabled image interpretation. Asia-Pacific demonstrates rapid adoption of both high-throughput CT platforms and novel hybrid imaging solutions, supported by strong hospital expansion and public health initiatives that prioritize early detection. Across regions, local manufacturing initiatives, regulatory harmonization efforts, and digital health investments are pivotal variables influencing device lifecycle strategies and commercial planning.
Competitive and collaborative strategies that manufacturers and innovators are deploying to secure clinical adoption and long-term service relationships in diagnostic imaging
Competitive dynamics are shaped as much by ecosystem orchestration as by device feature sets. Leading suppliers emphasize integrated offerings that combine modality-specific hardware with advanced software, enabling longitudinal patient surveillance and clinical decision support. Strategic collaborations between device manufacturers and software developers accelerate the translation of machine learning tools into validated clinical workflows, and partnerships with clinical networks support real-world evidence generation that underpins adoption and reimbursement discussions.
Commercial models are evolving toward outcome-linked service offerings and managed equipment plans that reduce upfront barriers for providers while ensuring post-deployment performance. Additionally, after-sales service excellence, rapid spare-parts availability, and remote diagnostics are increasingly decisive selection criteria. Smaller and niche innovators compete by focusing on adjacent capabilities such as point-of-care ultrasound, intravascular imaging enhancements, and domain-specific analytics, which can be integrated into larger vendor ecosystems. Taken together, competitive advantage is currently associated with demonstrable clinical value, service agility, and the ability to deliver validated software-driven insights that reduce diagnostic ambiguity and improve patient throughput.
Actionable strategic imperatives that senior executives and clinical leaders should implement to align technology investments with clinical value, supply resilience, and reimbursement readiness
Industry leaders should prioritize a set of pragmatic actions that align technological capability with clinical impact and commercial resilience. First, strengthen cross-functional engagement between clinical, procurement, and IT teams to ensure that purchases reflect total cost of ownership, interoperability requirements, and pathway integration rather than isolated capital decisions. Second, diversify supply chain strategies by qualifying alternate suppliers, evaluating regional assembly options, and negotiating service-level agreements that minimize downtime and protect clinical continuity.
Third, accelerate clinical validation of software tools through prospective registries and multicenter observational studies so that analytics-integrated modalities can be substantiated for reimbursement and guideline inclusion. Fourth, design flexible commercial models that accommodate capital-constrained providers, such as subscription-based imaging services, pay-per-use arrangements, or bundled diagnostics-and-treatment offerings. Finally, invest in workforce development and training programs to ensure that expanding modality capabilities translate into real-world diagnostic gains, emphasizing standardized protocols for perfusion, viability, and anatomical assessments to reduce inter-operator variability and enhance reproducibility.
A rigorous methodology integrating clinician interviews, device technical analysis, clinical evidence synthesis, and supply chain validation to support robust and actionable insights
The research foundation combines primary qualitative engagement with secondary clinical and technical literature to ensure robust triangulation of findings. Primary inputs include in-depth interviews with radiologists, cardiologists, hospital procurement leaders, imaging technologists, and device engineers to capture real-world device utilization, service expectations, and unmet clinical needs. These qualitative conversations are complemented by device-level technical specifications, regulatory filings, clinical guideline reviews, and peer-reviewed studies that document diagnostic performance characteristics and safety considerations.
Analytical processes include cross-validation of claims through independent clinical registry data and a synthesis of protocol-level evidence for anatomical, perfusion, and viability imaging. Supply chain mapping and tariff impact analysis were informed by industry procurement practices and vendor disclosures, and findings were subjected to expert validation rounds to refine interpretations. Throughout, emphasis was placed on reproducibility and clinical relevance, prioritizing methodologies that illuminate decision drivers for both acute and outpatient care settings while avoiding speculative numerical forecasting.
Synthesis of the strategic pathways through which imaging innovation, clinical validation, and procurement discipline will determine the future impact of coronary diagnostics
Diagnostic imaging for coronary heart disease is converging toward solutions that deliver multi-dimensional clinical insights while fitting within evolving care pathways and procurement realities. The combined trajectory of hardware refinement, software-enabled analytics, and adaptive commercial models is enabling earlier detection, more precise intervention planning, and streamlined patient management across acute and ambulatory settings. Nevertheless, tariff dynamics and supply chain pressures reinforce the need for strategic procurement and localized manufacturing considerations.
Ultimately, the ability of providers and manufacturers to translate technological capability into measurable clinical benefit will depend on disciplined clinical validation, interoperable architectures, and service models that prioritize uptime and long-term value. By focusing on these elements, stakeholders can better align investments with patient outcomes and system-level efficiency gains, ensuring that diagnostic imaging continues to play a central role in mitigating the global burden of coronary disease.
Note: PDF & Excel + Online Access - 1 Year
A focused orientation on how diagnostic imaging innovations and clinical imperatives are reshaping coronary heart disease detection, management, and care pathways
This executive summary provides a concise but comprehensive orientation to the evolving diagnostic imaging landscape for coronary heart disease, synthesizing technological advances, clinical practice shifts, and policy drivers that are shaping care pathways today. The intent is to equip healthcare leaders, device manufacturers, and clinical innovators with a clear view of the forces that define diagnostic choices, patient flow, and investment priorities across acute and outpatient settings.
To accomplish this, the narrative integrates clinical imperatives with device-level capabilities, emphasizes interoperability and workflow integration, and highlights how imaging modalities enable earlier detection, risk stratification, and therapy planning. By focusing on diagnostic value rather than output metrics, the summary outlines how imaging contributes to clinical decision-making, from anatomical characterization through perfusion and viability assessment, and positions imaging as an integral component of a patient-centric cardiovascular strategy.
How rapid hardware advancements, software-driven analytics, and care delivery model shifts are collectively redefining diagnostic imaging strategies for coronary heart disease
The diagnostic ecosystem for coronary heart disease is undergoing transformative shifts driven by faster volumetric acquisition, improved tissue characterization, and software-enabled interpretation. Advances in computed tomography now permit higher temporal and spatial resolution that supports low-dose coronary angiography and functional assessment in a single session. Concurrently, magnetic resonance imaging has extended its role beyond morphology to include refined quantitative perfusion and scar characterization, offering clinicians multiparametric insights without ionizing radiation.
Software convergence is accelerating change through artificial intelligence and advanced post-processing that automate segmentation, quantify perfusion, and generate reproducible biomarkers. These capabilities support triage in emergency departments, outpatient pre-procedural planning, and longitudinal disease monitoring. In parallel, workflow and care delivery models are evolving: imaging is migrating from tertiary centers into ambulatory and diagnostic center settings, while hybrid protocols that combine anatomical and physiological evaluation are increasingly adopted to reduce diagnostic uncertainty and guide intervention. Taken together, these shifts favor integrated solutions that pair modality-specific hardware improvements with cloud-native analytics and robust clinical validation.
Understanding the multi-dimensional ramifications of the 2025 tariff landscape on supply chains, procurement strategies, and device access across diagnostic imaging networks
The introduction of additional tariffs and trade adjustments in 2025 has created measurable pressure across the diagnostic imaging supply chain, prompting device vendors and healthcare providers to reassess procurement strategies and production footprints. Tariff-related input cost increases have particularly affected capital-intensive components and subassemblies, leading manufacturers to explore regional sourcing, revised supplier agreements, and strategic inventory positioning to mitigate lead-time exposures.
As a consequence, healthcare providers are confronting higher acquisition and service costs for certain imported imaging systems and parts, which has accelerated interest in refurbished systems, extended service contracts, and bundled financing. Policy responses and commercial strategies have emerged to preserve access: vendors are reconfiguring distribution models to localize key components, contract manufacturers are being engaged to diversify assembly locations, and providers are emphasizing total cost of ownership in procurement dialogues. Collectively, these adaptations aim to maintain clinical continuity while absorbing incremental cost pressures, and they underscore the importance of transparent supply chain mapping and proactive engagement with procurement and clinical stakeholders.
Deep segmentation insights that link modality classes, clinical applications, and care settings to optimize technology selection and workflow alignment for coronary diagnostics
A segmentation-centric view reveals where clinical need, technology capability, and care setting converge to influence adoption patterns. Across technology archetypes, computed tomography remains central for rapid coronary anatomical assessment, supported by distinct CT system classes such as dual-source CT that enable high temporal resolution, multi-slice CT platforms that balance coverage and throughput, and single-slice configurations that continue to serve lower-volume or niche use cases. Magnetic resonance imaging contributes complementary soft-tissue contrast and functional evaluation, delivered across field strengths that include 1.5T systems for broad clinical access, 3T platforms for higher signal-to-noise applications, and above 3T options in specialized research and advanced clinical centers.
Optical imaging modalities like intravascular optical coherence tomography and near-infrared spectroscopy advance vessel-level characterization during interventional workflows, while nuclear techniques including PET and SPECT provide molecular and metabolic insights that enhance viability and inflammation assessment. Ultrasound remains indispensable for bedside evaluation, evolving across 2D platforms for rapid anatomical assessment, 3D systems that enhance volumetric visualization, and Doppler modalities that quantify hemodynamic flow. End-user dynamics matter: ambulatory care centers and diagnostic centers are increasingly optimized for high-throughput non-invasive imaging, hospitals remain the focal point for acute, hybrid, and interventional diagnostics, and specialty clinics concentrate on longitudinal management. Application-driven segmentation further clarifies utility, spanning anatomical assessment for structural delineation, perfusion imaging for physiological evaluation with both resting and stress protocols, and viability imaging to inform revascularization and device therapy decisions. When considered together, these segmentation lenses underscore that procurement and deployment decisions should align modality selection with clinical pathways, throughput expectations, and the downstream implications for interventional planning and longitudinal patient management.
How regional policy frameworks, care delivery infrastructures, and capital investment patterns are driving differentiated adoption curves for coronary diagnostic imaging across global markets
Regional dynamics shape technology adoption, reimbursement pathways, and infrastructure investment in distinct ways across the globe. In the Americas, clinical guidelines, private payer frameworks, and a robust network of tertiary and community hospitals support rapid uptake of advanced CT and MRI protocols, while ambulatory diagnostic centers increasingly handle outpatient imaging volumes. Investment in integrated informatics and remote image review capabilities is notable, enabling broad clinician access despite geographic dispersion.
Europe, the Middle East and Africa exhibit heterogeneity driven by national health system priorities, regulatory landscapes, and variable capital availability. In several European markets, reimbursement alignment and centralized care pathways favor high-value imaging protocols and cross-center collaboration. The Middle East has accelerated capital investment in flagship centers, often targeting advanced modality installations and interventional imaging. Africa presents a mix of challenges and opportunity, with infrastructure constraints prompting interest in portable and cost-efficient ultrasound and cloud-enabled image interpretation. Asia-Pacific demonstrates rapid adoption of both high-throughput CT platforms and novel hybrid imaging solutions, supported by strong hospital expansion and public health initiatives that prioritize early detection. Across regions, local manufacturing initiatives, regulatory harmonization efforts, and digital health investments are pivotal variables influencing device lifecycle strategies and commercial planning.
Competitive and collaborative strategies that manufacturers and innovators are deploying to secure clinical adoption and long-term service relationships in diagnostic imaging
Competitive dynamics are shaped as much by ecosystem orchestration as by device feature sets. Leading suppliers emphasize integrated offerings that combine modality-specific hardware with advanced software, enabling longitudinal patient surveillance and clinical decision support. Strategic collaborations between device manufacturers and software developers accelerate the translation of machine learning tools into validated clinical workflows, and partnerships with clinical networks support real-world evidence generation that underpins adoption and reimbursement discussions.
Commercial models are evolving toward outcome-linked service offerings and managed equipment plans that reduce upfront barriers for providers while ensuring post-deployment performance. Additionally, after-sales service excellence, rapid spare-parts availability, and remote diagnostics are increasingly decisive selection criteria. Smaller and niche innovators compete by focusing on adjacent capabilities such as point-of-care ultrasound, intravascular imaging enhancements, and domain-specific analytics, which can be integrated into larger vendor ecosystems. Taken together, competitive advantage is currently associated with demonstrable clinical value, service agility, and the ability to deliver validated software-driven insights that reduce diagnostic ambiguity and improve patient throughput.
Actionable strategic imperatives that senior executives and clinical leaders should implement to align technology investments with clinical value, supply resilience, and reimbursement readiness
Industry leaders should prioritize a set of pragmatic actions that align technological capability with clinical impact and commercial resilience. First, strengthen cross-functional engagement between clinical, procurement, and IT teams to ensure that purchases reflect total cost of ownership, interoperability requirements, and pathway integration rather than isolated capital decisions. Second, diversify supply chain strategies by qualifying alternate suppliers, evaluating regional assembly options, and negotiating service-level agreements that minimize downtime and protect clinical continuity.
Third, accelerate clinical validation of software tools through prospective registries and multicenter observational studies so that analytics-integrated modalities can be substantiated for reimbursement and guideline inclusion. Fourth, design flexible commercial models that accommodate capital-constrained providers, such as subscription-based imaging services, pay-per-use arrangements, or bundled diagnostics-and-treatment offerings. Finally, invest in workforce development and training programs to ensure that expanding modality capabilities translate into real-world diagnostic gains, emphasizing standardized protocols for perfusion, viability, and anatomical assessments to reduce inter-operator variability and enhance reproducibility.
A rigorous methodology integrating clinician interviews, device technical analysis, clinical evidence synthesis, and supply chain validation to support robust and actionable insights
The research foundation combines primary qualitative engagement with secondary clinical and technical literature to ensure robust triangulation of findings. Primary inputs include in-depth interviews with radiologists, cardiologists, hospital procurement leaders, imaging technologists, and device engineers to capture real-world device utilization, service expectations, and unmet clinical needs. These qualitative conversations are complemented by device-level technical specifications, regulatory filings, clinical guideline reviews, and peer-reviewed studies that document diagnostic performance characteristics and safety considerations.
Analytical processes include cross-validation of claims through independent clinical registry data and a synthesis of protocol-level evidence for anatomical, perfusion, and viability imaging. Supply chain mapping and tariff impact analysis were informed by industry procurement practices and vendor disclosures, and findings were subjected to expert validation rounds to refine interpretations. Throughout, emphasis was placed on reproducibility and clinical relevance, prioritizing methodologies that illuminate decision drivers for both acute and outpatient care settings while avoiding speculative numerical forecasting.
Synthesis of the strategic pathways through which imaging innovation, clinical validation, and procurement discipline will determine the future impact of coronary diagnostics
Diagnostic imaging for coronary heart disease is converging toward solutions that deliver multi-dimensional clinical insights while fitting within evolving care pathways and procurement realities. The combined trajectory of hardware refinement, software-enabled analytics, and adaptive commercial models is enabling earlier detection, more precise intervention planning, and streamlined patient management across acute and ambulatory settings. Nevertheless, tariff dynamics and supply chain pressures reinforce the need for strategic procurement and localized manufacturing considerations.
Ultimately, the ability of providers and manufacturers to translate technological capability into measurable clinical benefit will depend on disciplined clinical validation, interoperable architectures, and service models that prioritize uptime and long-term value. By focusing on these elements, stakeholders can better align investments with patient outcomes and system-level efficiency gains, ensuring that diagnostic imaging continues to play a central role in mitigating the global burden of coronary disease.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of artificial intelligence algorithms for automated plaque characterization in coronary CT angiography
- 5.2. Integration of photon-counting computed tomography to improve coronary plaque visualization and quantification
- 5.3. Emergence of FFR-CT noninvasive fractional flow reserve assessment to guide coronary intervention decisions
- 5.4. Advancements in low-dose cardiac CT protocols to minimize radiation exposure in routine coronary screening
- 5.5. Expansion of point-of-care handheld ultrasound devices for bedside coronary flow reserve assessment
- 5.6. Utilization of hybrid PET/MRI systems for combined anatomical and molecular imaging of coronary inflammation
- 5.7. Development of novel molecular PET tracers targeting vulnerable atherosclerotic plaque biomarkers
- 5.8. Implementation of cloud-based platforms for remote cardiac imaging analytics and telecardiology collaboration
- 5.9. Integration of 3D printing technology for patient-specific coronary artery phantoms in preprocedural planning
- 5.10. Incorporation of deep learning-driven workflow automation to streamline cardiac imaging report generation
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Coronary Heart Disease Diagnostic Imaging Devices Market, by Technology
- 8.1. CT
- 8.1.1. Dual-Source CT
- 8.1.2. Multi-Slice CT
- 8.1.3. Single-Slice CT
- 8.2. MRI
- 8.2.1. 1.5T
- 8.2.2. 3T
- 8.2.3. Above 3T
- 8.3. Optical Imaging
- 8.3.1. IVOCT
- 8.3.2. NIRS
- 8.4. PET
- 8.5. SPECT
- 8.6. Ultrasound
- 8.6.1. 2D
- 8.6.2. 3D
- 8.6.3. Doppler
- 9. Coronary Heart Disease Diagnostic Imaging Devices Market, by Application
- 9.1. Anatomical Assessment
- 9.2. Perfusion Imaging
- 9.2.1. Resting Perfusion
- 9.2.2. Stress Perfusion
- 9.3. Viability Imaging
- 10. Coronary Heart Disease Diagnostic Imaging Devices Market, by End User
- 10.1. Ambulatory Care Centers
- 10.2. Diagnostic Centers
- 10.3. Hospitals
- 10.4. Specialty Clinics
- 11. Coronary Heart Disease Diagnostic Imaging Devices Market, by Region
- 11.1. Americas
- 11.1.1. North America
- 11.1.2. Latin America
- 11.2. Europe, Middle East & Africa
- 11.2.1. Europe
- 11.2.2. Middle East
- 11.2.3. Africa
- 11.3. Asia-Pacific
- 12. Coronary Heart Disease Diagnostic Imaging Devices Market, by Group
- 12.1. ASEAN
- 12.2. GCC
- 12.3. European Union
- 12.4. BRICS
- 12.5. G7
- 12.6. NATO
- 13. Coronary Heart Disease Diagnostic Imaging Devices Market, by Country
- 13.1. United States
- 13.2. Canada
- 13.3. Mexico
- 13.4. Brazil
- 13.5. United Kingdom
- 13.6. Germany
- 13.7. France
- 13.8. Russia
- 13.9. Italy
- 13.10. Spain
- 13.11. China
- 13.12. India
- 13.13. Japan
- 13.14. Australia
- 13.15. South Korea
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2024
- 14.2. FPNV Positioning Matrix, 2024
- 14.3. Competitive Analysis
- 14.3.1. Agfa-Gevaert Group
- 14.3.2. AngioDynamics, Inc.
- 14.3.3. Canon Medical Systems Corporation
- 14.3.4. Edwards Lifesciences Corporation
- 14.3.5. Epsilon Imaging, Inc.
- 14.3.6. FUJIFILM Corporation
- 14.3.7. GE HealthCare Technologies Inc.
- 14.3.8. Heart Test Laboratories, Inc.
- 14.3.9. Hill-Rom Holdings, Inc.
- 14.3.10. Hitachi, Ltd.
- 14.3.11. Koninklijke Philips N.V.
- 14.3.12. LivaNova PLC
- 14.3.13. Merit Medical Systems, Inc.
- 14.3.14. Siemens AG
- 14.3.15. Terumo Medical Corporation
- 14.3.16. TOMTEC Imaging Systems GmbH
- 14.3.17. Translumina GmbH
- 14.3.18. Analogic Corporation
- 14.3.19. Toshiba Corporation
- 14.3.20. Mindray Medical International Limited
- 14.3.21. Chison Medical Technologies Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
